Author of

• 17629

  +

  P2.03b - Poster Session with Presenters Present (ID 465)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17710

    +

    P2.03b-081 - Comparison of Genomic Alterations Derived from Matched Tumor Tissue and Liquid Biopsy (ID 6010)

    14:30 - 14:30  |  Author(s): J. Heuckmann
    • Abstract

    Background:
    In the last decade, translational research led to the identification of oncogenic drivers and the successful development of targeted inhibitors. Today, especially patients with lung carcinoma with a non-squamous histology benefit from targeted inhibition, for example of EGFR, ALK, ROS1, MET. However, in many cases tumor material is limited and does not allow for complete molecular diagnostics or, in a relapse setting, a re-biopsy may not be possible. Thus, reliable and comprehensive detection of genomic alterations by non-invasive means, such as liquid biopsies are required. In addition, repeated analysis of cell-free tumor DNA allows for disease monitoring while, at the same time, displaying the tumor heterogeneity.
    
    Methods:
    At NEO New Oncology we have developed two hybrid-capture based NGS assays, designed for the detection of genomic alterations in tissue or blood with high sensitivity and specificity. NEOplus is applied to FFPE tumor tissue and detects somatic alterations in a panel of more than 90 cancer related genes. NEOliquid is specifically designed for detection of genomic alterations from cell-free DNA of liquid biopsies and covers a panel of 39 clinically relevant genes. To evaluate the performance of liquid biopsies in the routine setting, we applied both NEO tests on matched FFPE and blood samples to correlated results.
    
    Results:
    Overall, a selection of matched FFPE and blood samples of more than 60 patients with non-squamous histology were analyzed. We were able to identify the same therapy relevant genomic alterations in FFPE and blood samples in a majority of the cases. Discrepancies in mutation spectrum of the blood and tissue sample were due to insufficient tumor DNA in cfDNA as well as tumor heterogeneity across multiple tumor manifestations.
    
    Conclusion:
    By comparing 60 matched tissue and blood sample we were able to identify concordant mutations across a broad spectrum of genes.